8-K: CooperCompanies Reports Strong Q1 2026, Raises Guidance

CooperCompanies announced robust first quarter 2026 financial results, exceeding expectations and leading to an upward revision of its full-year earnings and free cash flow guidance.

Summary

• First quarter 2026 revenue reached $1.024 billion, marking a 6% increase year-over-year, or 3% organically.
• GAAP diluted earnings per share (EPS) for Q1 2026 was $0.66, up 27% from the prior year.
• Non-GAAP diluted EPS for Q1 2026 was $1.10, an increase of 20% year-over-year.
• Operating margins surpassed expectations, attributed to disciplined execution and significant synergies from last year's reorganization.
• The company generated strong free cash flow of $158.7 million during the quarter.
• CooperCompanies repurchased $92.5 million of common stock, approximately 1.1 million shares, at an average price of $82.04.
• Fiscal year 2026 financial guidance was raised for total revenue, non-GAAP diluted EPS, and free cash flow.

Sentiment

Score: 8

Explanation: StockSavvy.ai views this as a very positive report, driven by strong financial performance, successful product launches, improved profitability, and an upward revision of full-year guidance, indicating strong operational execution and strategic confidence.

Positives

• Q1 2026 revenue increased 6% to $1.024 billion, with organic growth of 3%.
• GAAP diluted EPS rose 27% to $0.66, and Non-GAAP diluted EPS increased 20% to $1.10.
• Operating margins exceeded expectations, with GAAP operating margin at 21% and Non-GAAP operating margin at 27%, reflecting disciplined execution and meaningful synergies.
• Strong free cash flow of $158.7 million was generated in the quarter.
• Successful product launches, including early traction from the MyDay MiSight portfolio, contributed to revenue growth.
• Interest expense decreased to $22.4 million from $26.0 million in the prior year, driven by lower average debt.
• The company raised its fiscal year 2026 guidance for total revenue, non-GAAP diluted EPS ($4.58 $4.66), and free cash flow ($600 $625 million).
• Ongoing share repurchases supported capital allocation, with $873.9 million remaining availability.
• The company remains on track with its long-term outlook for generating over $2.2 billion in free cash flow from 2026 through 2028.

Negatives

• Non-GAAP gross margin was down 60 basis points from last year to 68%, although it would have been flat year over year excluding the impact of tariffs.
• Currency impact negatively affected reported revenue growth, with total revenue up 6% reported but 3% in constant currency.
• CooperVision's Asia Pacific revenue decreased 4% both on a reported and constant currency basis.

Risks

• Adverse changes in global or regional general business, political, and economic conditions, including uncertainty and instability in certain countries, man-made or natural disasters, and pandemic conditions.
• The impact of international conflicts, such as the ongoing conflict in the Middle East, on the global and local economy, financial markets, energy markets, currency rates, and the ability to supply products.
• Challenges associated with managing substantial and expanding international operations and complying with diverse legal, compliance, and regulatory requirements across multiple countries.
• The actual imposition or threats of tariffs, customs duties, and fees by the U.S. government and other nations, and other retaliatory trade actions.
• Foreign currency exchange rate and interest rate fluctuations, including the risk of fluctuations that would decrease net sales and earnings.
• The impact of rate increases on existing and future variable rate indebtedness and associated interest expense, which could adversely affect financial health or limit borrowing ability.
• Changes in tax laws, examinations by tax authorities, and changes in the geographic composition of income.
• Acquisition-related adverse effects, including failure to achieve anticipated benefits, integration delays or costs, issues with regulatory approvals, changes to accounting controls, contingent liabilities, increased leverage, and lack of access to financing.
• Compliance costs and potential liability related to U.S. and foreign laws and healthcare regulations pertaining to privacy and security of personal information, including those resulting from data security breaches.
• Major disruptions in the operations of manufacturing, accounting, financial reporting, research and development, distribution facilities, or raw material supply chain due to integration challenges, disasters, pandemics, cybersecurity incidents, or third-party vendor failures.
• Market consolidation of large customers globally through mergers or acquisitions, resulting in a larger proportion or concentration of business being derived from fewer customers.
• Disruptions in supplies of raw materials, particularly components used to manufacture silicone hydrogel lenses.
• New U.S. and foreign government laws and regulations, and changes in existing laws, regulations, and enforcement guidance, affecting the healthcare and medical device industries.
• Legal costs, insurance expenses, settlement costs, and the risk of adverse decisions, prohibitive injunctions, or settlements related to product liability, patent infringement, contractual disputes, or other litigation.
• Limitations on sales following product introductions due to poor market acceptance.
• New competitors, product innovations or technologies, including technological advances by competitors, new products and patents attained by competitors, and competitors' expansion through acquisitions.
• Reduced sales, loss of customers, reputational harm, and costs and expenses, including from claims and litigation related to product recalls and warning letters.
• Failure to receive, or delays in receiving, regulatory approvals or certifications for products.
• Failure of customers and end users to obtain adequate coverage and reimbursement from third-party payers for products and services.
• The requirement to provide for a significant liability or to write off, or accelerate depreciation on, a significant asset, including goodwill, other intangible assets, and idle manufacturing facilities and equipment.
• The success of research and development activities and other start-up projects.
• Dilution to earnings per share from acquisitions or issuing stock.
• Impact and costs incurred from changes in accounting standards and policies.
• Risks related to environmental laws and requirements applicable to facilities, products, or manufacturing processes, including evolving regulations regarding hazardous substances.
• Risks related to environmental, social, and corporate governance issues, including those related to regulatory and disclosure requirements, climate change, and sustainability.

Future Outlook

The company updated its fiscal year 2026 financial guidance, projecting total revenue between $4.306 billion and $4.346 billion (4.5% to 5.5% organic growth), non-GAAP diluted EPS of $4.58 to $4.66, and free cash flow of $600 million to $625 million. Management remains on track to generate over $2.2 billion in free cash flow from 2026 through 2028, providing meaningful flexibility to invest in growth drivers, continue share repurchases, and reduce debt.

Management Comments

• "We're pleased to report a strong start to the fiscal year, highlighted by product launches, outstanding profitability, and robust cash flow, all of which gives us the confidence to raise both earnings and free cash flow guidance."
• "Revenue growth benefited from continued strength in our premium MyDay portfolio, and momentum is building from product launches including early traction from MyDay MiSight."
• "Operating margins exceeded expectations, reflecting disciplined execution and the meaningful synergies delivered through last year's reorganization."
• "These improvements are strengthening our foundation--enhancing efficiency, improving our cost structure, and enabling more targeted investment in our highest-return opportunities."
• "Our strong free cash flow also supported ongoing share repurchases, which remain a core element of our capital-allocation strategy."
• "Combined with improved organizational alignment and progress across our key initiatives, we believe we are well positioned to build momentum as the year progresses."
• "Importantly, we remain on track with our long-term outlook for generating more than $2.2 billion in free cash flow from 2026 through 2028, providing meaningful flexibility to invest in growth drivers, continue share repurchases, and reduce debt."

Industry Context

StockSavvy.ai notes that CooperCompanies' strong performance in contact lenses, particularly with its premium MyDay portfolio and new product launches like MyDay MiSight, aligns with broader industry trends favoring advanced vision care solutions. The robust growth in fertility and women's healthcare through CooperSurgical also reflects increasing demand in specialized medical device sectors. The company's focus on operational efficiency and strategic capital allocation, including share repurchases and debt reduction, positions it well within a competitive medical device landscape.

Legal Proceedings

• Charges included $6.7 million related to legal matters in the three months ended January 31, 2026.
• Charges included $0.6 million related to legal matters in the three months ended January 31, 2025.
• Forward-looking statements highlight risks related to legal costs, insurance expenses, settlement costs, and the risk of adverse decisions, prohibitive injunctions, or settlements concerning product liability, patent infringement, contractual disputes, or other litigation.

Stakeholder Impact

• Shareholders: Positive impact due to strong financial performance, increased EPS, ongoing share repurchases, and raised guidance, which could lead to increased share value.
• Employees: Potential positive impact from improved organizational alignment and efficiency, though past periods included 'redundant personnel costs for transitional employees' as part of business optimization.
• Customers: Positive impact from continued strength in premium product portfolios (e.g., MyDay) and new product launches (e.g., MyDay MiSight), offering advanced solutions.
• Creditors: Positive impact from lower average debt and robust free cash flow, enhancing the company's ability to service its debt obligations.
• Suppliers: Potential for stable or increased demand for raw materials and components given the company's growth and product launches.

Next Steps

• Continue to build momentum as the fiscal year progresses.
• Invest in growth drivers across both CooperVision and CooperSurgical segments.
• Continue with the share repurchase program, utilizing the remaining $873.9 million availability.
• Reduce debt, leveraging strong free cash flow generation.
• Host an audio webcast and conference call on March 5, 2026, at 5:00 PM ET to discuss first quarter results and current corporate developments.

Key Dates

Recommendation

The company delivered robust first-quarter results, exceeding expectations across key financial metrics including revenue and EPS. The upward revision of full-year guidance for revenue, non-GAAP EPS, and free cash flow signals strong management confidence and operational momentum. Strategic initiatives like successful product launches, improved operating margins through reorganization synergies, and ongoing share repurchases further enhance shareholder value. The strong free cash flow generation and commitment to debt reduction provide significant financial flexibility, making this an attractive investment opportunity.

Keywords

CooperCompanies, COO, Medical Device, Contact Lenses, Women's Healthcare, Fertility, CooperVision, CooperSurgical, Financial Results, Earnings, Revenue, EPS, Guidance, Share Repurchase, Free Cash Flow, Q1 2026